We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Technology 14.31%
3 Communication Services 13.23%
4 Financials 10.05%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVR
76
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
$28.7M 0.17%
+82,603
New +$26.8M
DMTK
77
DELISTED
DermTech, Inc. Common Stock
DMTK
$27.9M 0.17%
861,090
-358,909
-29% -$5.09M
BIIB icon
78
Biogen
BIIB
$32B
$25.2M 0.15%
+103,000
New +$26.6M
CNST
79
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$21.6M 0.13%
+750,000
New +$18.9M
BEKE icon
80
KE Holdings
BEKE
$19.6B
$21.1M 0.13%
343,000
+8,000
+2% +$532K
GRFS
81
Grifois
GRFS
$5.44B
$20.6M 0.12%
1,115,000
-2,013,750
-64% -$37.3M
ZEAL
82
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$18.3M 0.11%
510,000
+5,000
+1% +$188K
ATTO
83
DELISTED
Atento S.A.
ATTO
$18.2M 0.11%
2,230,357
– –
PLRX icon
84
Pliant Therapeutics
PLRX
$71.8M
$17.4M 0.1%
764,262
– –
DCPH
85
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17.1M 0.1%
300,000
-30,000
-9% -$1.78M
INBX
86
DELISTED
Inhibrx, Inc. Common Stock
INBX
$16.8M 0.1%
510,000
+115,000
+29% +$3.06M
RC
87
Ready Capital
RC
$311M
$16.8M 0.1%
1,350,226
– –
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$16.3M 0.1%
150,000
– –
BMY icon
89
Bristol-Myers Squibb
BMY
$137B
$15.5M 0.09%
250,000
-3,500,000
-93% -$215M
BMY.RT
90
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$14.8M 0.09%
21,400,000
-22,673,000
-51% -$48.3M
PRAX icon
91
Praxis Precision Medicines
PRAX
$10.5B
$13.8M 0.08%
+16,667
New +$9.73M
XPO icon
92
XPO
XPO
$23.2B
$13.1M 0.08%
+318,053
New +$11.5M
NTLA icon
93
Intellia Therapeutics
NTLA
$1.8B
$12.2M 0.07%
+225,000
New +$8.17M
TINV.U
94
DELISTED
Tiga Acquisition Corp. Units, each consisting of one Class A ordinary share and one half of one warrant
TINV.U
$11.4M 0.07%
+1,080,000
New +$11.2M
TECX
95
Tectonic Therapeutic
TECX
$736M
$11.1M 0.07%
66,250
-21,250
-24% -$3.78M
RCKT icon
96
Rocket Pharmaceuticals
RCKT
$385M
$11M 0.07%
+200,000
New +$7.29M
QURE icon
97
uniQure
QURE
$3.36B
$10.8M 0.07%
300,000
-150,000
-33% -$6.33M
CAS.U
98
DELISTED
Cascade Acquisition Corp. Units, each consisting of one share of Class A Common Stock and one-half o
CAS.U
$10.3M 0.06%
+990,000
New +$10.1M
KNTE
99
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$9.95M 0.06%
+250,000
New +$10M
ALBO
100
DELISTED
Albireo Pharma Inc
ALBO
$9.38M 0.06%
250,000
+50,000
+25% +$1.82M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2020 Portfolio in Review

As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
  • Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.